We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Redx Pharma Plc | LSE:REDX | London | Ordinary Share | GB00BSNB6S51 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.00 | -10.00% | 9.00 | 8.00 | 10.00 | 9.00 | 9.00 | 9.00 | 670,146 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.2M | -33.16M | -0.0852 | -1.06 | 35.01M |
TIDMREDX
RNS Number : 5804O
Redx Pharma plc
11 October 2021
REDX PHARMA PLC
("Redx" or the "Company")
Redx Virtual R&D Day with Leading Experts and New Clinical Data for ROCK2 Inhibitor
Encouraging new data shows selective ROCK2 inhibitor RXC007 has an excellent safety and pharmacokinetic profile in ongoing Phase 1 study
RXC004 Phase 2 programme to commence in Q4 2021 in Wnt-ligand driven tumours
Redx's discovery engine targeting three new INDs by 2025
Alderley Park, UK, 11 October 2021 - Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces it is hosting a Virtual R&D Day later today between 1:00pm-2:30pm BST (8:00am-9:30am EDT).
The R&D Day will feature updates from the Company's leadership team and presentations from leading experts in the fields of colorectal cancer and fibrosis. Focus will be on Redx's wholly owned lead product RXC004, a selective Porcupine inhibitor. Redx plans to commence a global Phase 2 monotherapy programme with RXC004 in three cancer types with Wnt-ligand dependent tumours: microsatellite stable metastatic colorectal cancer, pancreatic cancer and biliary tract cancer. RXC004 is also currently being investigated in a Phase 1 study in combination with the anti-PD-1antibody nivolumab.
There will also be an update on the wholly owned selective ROCK2 inhibitor RXC007, being developed for idiopathic pulmonary fibrosis. Encouraging new clinical data from the ongoing RXC007 Phase 1 study* in healthy volunteers shows:
-- An excellent safety and pharmacokinetic profile -- No adverse events following single dose of 2-40 milligram -- Pharmacokinetics as predicted from preclinical data -- Essentially linear exposure for 2-40 milligram -- Biologically relevant exposures achieved at higher doses -- At 40 milligram the half-life was approximately 11 hours, suitable for once-daily dosing
The R&D event includes presentations from leading experts:
-- Professor Scott Kopetz, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
-- Professor Gisli Jenkins, Faculty of Medicine, National Heart & Lung Institute, Imperial College London
-- Professor Toby Maher, Professor of Medicine and Director of Interstitial Lung Disease, Keck School of Medicine, University of Southern California, Los Angeles
To register and receive a link to view the webcast, please email redxpharma@fticonsulting.com. A recording of the webcast will be available on Redx's website www.redxpharma.com following the event.
*Clinicaltrials.gov identifier NCT04931147; data cut-off date 14 September 2021
For further information, please contact: Redx Pharma Plc T: +44 (0)1625 469 918 UK Headquarters Lisa Anson, Chief Executive Officer Karl Hård, Head of Investor Relations k.hard@redxpharma.com US Office Peter Collum, Chief Financial Officer SPARK Advisory Partners (Nominated Adviser) T: +44 (0)203 368 3550 Matt Davis/Adam Dawes WG Partners LLP (Joint Broker) T: +44 (0)203 705 9330 Claes Spång/Nigel Birks/David Wilson Panmure Gordon (UK) Limited (Joint Broker) T: +44 (0)207 886 2500 Rupert Dearden/Freddy Crossley/Emma Earl FTI Consulting T: +44 (0)203 727 1000 Simon Conway/Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept, before evaluating options for further development and potential value creation. Redx's lead oncology asset, the Porcupine inhibitor RXC004, is expected to commence a Phase 2 programme in H2 2021. The Company's selective ROCK2 inhibitor, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical study in June 2021 for which results are expected in 2022.
The Company has a strong track record of discovering new drug candidates through its core capability of converting medicinal chemistry insights into differentiated and commercially attractive drug candidates, with five proprietary or partnered assets in late pre-clinical or clinical development. One of those assets, a BTK inhibitor - pirtobrutinib/LOXO-305 - was sold to Loxo Oncology (now Eli Lilly) and is currently in Phase 3 clinical studies in chronic lymphocytic leukaemia. In addition, Redx has forged pre-clinical asset partnerships with other blue chip companies including AstraZeneca and Jazz Pharmaceuticals.
To subscribe to Email alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCFFFIVIVLILIL
(END) Dow Jones Newswires
October 11, 2021 02:00 ET (06:00 GMT)
1 Year Redx Pharma Chart |
1 Month Redx Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions